𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A study of the efficacy and safety of transurethral needle ablation (TUNA®) treatment for benign prostatic hyperplasia

✍ Scribed by R. J. Millard; L. M. Harewood; K. Tamaddon


Publisher
John Wiley and Sons
Year
1996
Tongue
English
Weight
777 KB
Volume
15
Category
Article
ISSN
0733-2467

No coin nor oath required. For personal study only.


📜 SIMILAR VOLUMES


Nd:YAG laser ablation of the prostate as
✍ Dr. Anthony J. Costello; Douglas E. Johnson; Damien M. Bolton 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 393 KB

Many techniques have been used to relieve obstructive symptoms associated with benign prostatic hypertrophy. Transurethral resection of the prostate (TURP) with an electrocautery loop is the most commonly performed operation to relieve bladder neck and urethral obstruction caused by prostatic adenom

Urodynamic effects of silodosin, a new α
✍ Tomonori Yamanishi; Tomoya Mizuno; Katsuhisa Tatsumiya; Miho Watanabe; Takao Kam 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 109 KB

## Aims: To investigate urodynamically the effects of silodosin, a new alpha(1a)-adrenoceptor-selective antagonist, in the treatment of benign prostatic hyperplasia (bph). ## Methods: Thirty six male patients with bph (69.9 +/- 7.3 years), who were referred as candidates for surgery, were treated

ChemInform Abstract: An Improved Synthes
✍ Gee-Hong Kuo; Catherine Prouty; William V. Murray; Rekha D. Shah 📂 Article 📅 2010 🏛 John Wiley and Sons ⚖ 39 KB 👁 1 views

## Abstract ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 100 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable v

Efficacy of radiotherapy for ovarian abl
✍ Lorie L. Hughes; Robert J. Gray; Lawrence J. Solin; Nicholas J. Robert; Silvana 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB

## Abstract ## BACKGROUND In 1994, the Eastern Cooperative Oncology Group (ECOG) initiated for the Breast Intergroup a randomized clinical trial (E3193) in premenopausal patients with early‐stage breast carcinoma (lymph node‐negative and receptor‐positive, with tumors measuring ≤ 3 cm) comparing t